Literature DB >> 15319430

Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors.

Stefan Wüller1, Burkhard Wiesner, Anja Löffler, Jens Furkert, Gerd Krause, Ricardo Hermosilla, Michael Schaefer, Ralf Schülein, Walter Rosenthal, Alexander Oksche.   

Abstract

Some membrane-permeable antagonists restore cell surface expression of misfolded receptors retained in the endoplasmic reticulum (ER) and are therefore termed pharmacochaperones. Whether pharmacochaperones increase protein stability, thereby preventing rapid degradation, or assist folding via direct receptor interactions or interfere with quality control components remains elusive. We now show that the cell surface expression and function (binding of the agonist) of the mainly ER-retained wild-type murine vasopressin V2 receptor GFP fusion protein (mV2R.GFP) is restored by the vasopressin receptor antagonists SR49059 and SR121463B with EC50 values similar to their KD values. This effect was preserved when protein synthesis was abolished. In addition, SR121463B rescued eight mutant human V2Rs (hV2Rs, three are responsible for nephrogenic diabetes insipidus) characterized by amino acid exchanges at the C-terminal end of transmembrane helix TM I and TM VII. In contrast, mutants with amino acid exchanges at the interface of TM II and IV were not rescued by either antagonist. The mechanisms involved in successful rescue of cell surface delivery are explained in a three-dimensional homology model of the antagonist-bound hV2R.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319430     DOI: 10.1074/jbc.M408154200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Adenosine A2A receptor is involved in cell surface expression of A2B receptor.

Authors:  Kengo Moriyama; Michail V Sitkovsky
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

Review 2.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

3.  The pseudo signal peptide of the corticotropin-releasing factor receptor type 2a decreases receptor expression and prevents Gi-mediated inhibition of adenylyl cyclase activity.

Authors:  Katharina Schulz; Claudia Rutz; Carolin Westendorf; Ingrid Ridelis; Susanne Vogelbein; Jens Furkert; Antje Schmidt; Burkhard Wiesner; Ralf Schülein
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

4.  GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors.

Authors:  Randa S Eshaq; Letha D Stahl; Randolph Stone; Sheryl S Smith; Lucy C Robinson; Nancy J Leidenheimer
Journal:  Brain Res       Date:  2010-05-16       Impact factor: 3.252

Review 5.  Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects.

Authors:  Henry A Lester; Julie M Miwa; Rahul Srinivasan
Journal:  Biol Psychiatry       Date:  2012-07-06       Impact factor: 13.382

Review 6.  Regulation of G protein-coupled receptor export trafficking.

Authors:  Chunmin Dong; Catalin M Filipeanu; Matthew T Duvernay; Guangyu Wu
Journal:  Biochim Biophys Acta       Date:  2006-09-23

7.  Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.

Authors:  Jo Ann Janovick; Shaun P Brothers; Anda Cornea; Eugene Bush; Mark T Goulet; Wallace T Ashton; Daryl R Sauer; Fortuna Haviv; Jonathan Greer; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2007-05-03       Impact factor: 4.102

8.  Coregulation of natively expressed pertussis toxin-sensitive muscarinic receptors with G-protein-activated potassium channels.

Authors:  Sinead M Clancy; Stephanie B Boyer; Paul A Slesinger
Journal:  J Neurosci       Date:  2007-06-13       Impact factor: 6.167

Review 9.  Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Trends Endocrinol Metab       Date:  2009-12-11       Impact factor: 12.015

10.  The N terminus of monoamine transporters is a lever required for the action of amphetamines.

Authors:  Sonja Sucic; Stefan Dallinger; Barbara Zdrazil; René Weissensteiner; Trine N Jørgensen; Marion Holy; Oliver Kudlacek; Stefan Seidel; Joo Hwan Cha; Ulrik Gether; Amy H Newman; Gerhard F Ecker; Michael Freissmuth; Harald H Sitte
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.